Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$21.76
-$0.05(-0.51%)
At close: 4:00 PM EST
$21.76
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$8.16 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)835.24K
Market Cap
$1.21B
Enterprise Value$940.75M
Total Cash (Recent Filing)$343.19M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
May 14, 2026EPS Estimate
-1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding57,361,260
10 Day Avg. Volume636,073
30 Day Avg. Volume835,244
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue94.07
Enterprise Value/Gross Profit-24.73
Enterprise Value/Ebitda-4.44
Forecast
1Y Price Target
$43.50Price Target Upside99.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.5
Revenue Forecast (FY)$9.38M
Bulls Say, Bears Say
Bulls Say
Patient-friendly Administration And Physician InterestPhysician feedback points to strong prescribing interest in obexelimab driven by at-home subcutaneous dosing, faster B-cell recovery, and favorable pharmacoeconomics, which could favor outpatient uptake versus intravenous alternatives.
Pipeline And Lifecycle ExpansionManagement's program to develop a longer-acting form of obex combined with ongoing development of an oral BTK inhibitor for progressive multiple sclerosis broadens potential indications and supports future commercial opportunities.
Registrational Phase 3 SuccessAnalyst highlights that obexelimab met its primary endpoint in a registrational Phase 3 trial for IgG4-related disease, demonstrating reduced disease flares and a favorable safety profile that supports approval prospects and market entry.
Bears Say
Competitive Threat From Cytolytic CD19 AntibodyA competing cytolytic antibody targeting CD19 with strong efficacy could challenge obexelimab's market positioning and reduce potential share despite obexelimab's dosing and safety advantages.
Perceived Clinical Competitiveness Versus RivalsPerception that a late-stage trial was less impressive than a rival therapy may dampen commercial enthusiasm and make market penetration more difficult even after achieving statistical success.
Regulatory Uncertainty For Multiple SclerosisUncertainty about acceptable regulatory endpoints for relapsing multiple sclerosis creates strategic risk that could complicate development plans and limit clarity on approval pathways for CNS-focused programs.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $8.16 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.21B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 26 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Mar 16, 2026. The company reported -$4.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$3.539.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.47.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 57,361,260 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$4.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -3.369%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.50 (99.91% Upside)
$43.50 (99.91% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
161.22%
12-Months-Change
Fundamentals
Return on Equity
-156.98%
Trailing 12-Months
Asset Growth
3.70%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$43.50
▲(99.91% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---